FDA Approves J&J’s Topamax For Preventing Migraines in Adolescents

The Food and Drug Administration March 28 approved Topamax (topiramate) for preventing migraine headaches in adolescents ages 12 to 17.

This is the first FDA approval of a drug for migraine prevention in this age group, the agency said. The medication is taken on a daily basis to reduce the frequency of migraine headaches.

Topamax, which is manufactured by Janssen Pharmaceuticals Inc. of Titusville, N.J., first was approved by the FDA in 1996 to prevent seizures. It was approved for migraine prevention in adults in 2004. Janssen is part of Johnson & Johnson.

“Migraine headaches can impact school performance, social ...